Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics Working Capital

The Working Capital of Aspira Pathlab & Diagnostics (540788.BO) as of Nov 2, 2026 is 29.92 M INR. In the previous year, Working Capital was 22.84 M INR — a change of 31.00% (higher).

Working Capital

29.92 MINR

YoY

31.00%

Last updated:

Working Capital of Aspira Pathlab & Diagnostics is 2025 29.92 M INR. Working Capital of Aspira Pathlab & Diagnostics was 2024 22.84 M INR. It decreases by 31.00% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aspira Pathlab & Diagnostics Stock analysis

What does Aspira Pathlab & Diagnostics do? Aspira Pathlab & Diagnostics Ltd generates revenue through pathology investigation services, radiology investigation services, and health packages at its diagnostic centers in Mumbai. The company offers specialized tests such as the Shanti Screening Test, COVID-19 Antibody Test, and COVID-19 RT-PCR Test, which are part of its diagnostic services portfolio. Customers include individuals seeking health screenings, patients requiring medical diagnostics, and healthcare providers who refer clients to its facilities. The firm's services are segmented into pathology, radiology, and health packages, with a focus on high-demand tests like COVID-19 detection profiles. The company's revenue streams are derived from conducting various pathological investigations across branches like biochemistry, hematology, and microbiology. Its health packages and pathology tests, including the COVID-19 Detection Profile 1 and 2, cater to both individual and institutional clients. The firm operates within the healthcare sector, providing diagnostic solutions for patients and medical professionals in Mumbai, with a particular emphasis on pandemic-related testing services during the global health crisis. Aspira Pathlab & Diagnostics Ltd monetizes its diagnostic capabilities through a mix of routine pathology services and specialized health packages. The Shanti Screening Test and other COVID-19-related tests form a significant portion of its revenue, especially during periods of high demand for pandemic testing. The company serves a broad customer base, including individuals, clinics, and hospitals that rely on its diagnostic expertise for accurate medical assessments. Aspira Pathlab & Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aspira Pathlab & Diagnostics stock

Working Capital of Aspira Pathlab & Diagnostics is 29.92 M INR in 2025.

Working Capital of Aspira Pathlab & Diagnostics changed from 22.84 M INR to 29.92 M INR, representing a 31.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Aspira Pathlab & Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Aspira Pathlab & Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aspira Pathlab & Diagnostics

All Key Metrics — Aspira Pathlab & Diagnostics